<DOC>
	<DOCNO>NCT02679339</DOCNO>
	<brief_summary>Study 2022-HZ-011 utilize randomize withdrawal ( RW ) , double-blind , placebo control design PK safety CNTX 2022 ( 40 % anhydrous lidocaine gel ) evaluate subject acute-onset herpes zoster pain .</brief_summary>
	<brief_title>Study Evaluate Safety Pharmacokinetics Topically Applied 40 % Lidocaine Gel Compared With Placebo Subjects With Acute Herpes Zoster ( Shingles ) Pain</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>1 . Subject male female ≥ 18 year age ≤ 85 year age . 2 . Subject brushevoked allodynic pain intensity score ≥ 4 use NPRS determine pain assessment physical examination screening . a. Onset must occur ≤ 20 day prior randomization 3 . Subject average daily pain intensity score ≥ 4 use NPRS determine pain assessment physical examination screening . 4 . Subject must diagnosis herpes zoster ( shingle ) . 5 . Subject rash limit trunk limb , total surface area 300 cm2 . 1 . Subject active herpes zoster lesion face , head , neck , genital rectal area . 2 . Subject rash limit trunk limb , total surface area great 300 cm2 . 3 . Subject known history allergic reaction , hypersensitivity , clinically significant intolerance lidocaine , ingredient study drug , local anesthetic amide type . 4 . Subject target skin area ( allodynic area surround skin ) intact , inflame , opinion Principal Investigator , consistent rash due acute herpes zoster . 5 . Subject form pain discernible herpes zoster ( shingle ) allodynia . 6 . Subject take Class I antiarrhythmic drug ( e.g. , tocainide , mexiletine ) , medication could interact study drug interfere evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>